David J. Brillon, M.D.

Endocrinology, Diabetes and Metabolism
David Brillon

Endocrinology, with its emphasis on diagnostic reasoning and the interpretation of myriad metabolic profiles and hormonal feedback loops, has fascinated me since medical school.  During my clinical training as a medical resident, I witnessed the dramatic improvement in the health of patients when replacement therapy, such as insulin or thyroid hormone, is supplied to individuals with endocrine deficiencies.

The scientific interest and ability to significantly improve the lives of my patients led me to pursue a career in endocrinology.  For the past 24 years, I have been involved with research in the hormonal control of glucose metabolism as well as clinical studies evaluating the effect of glucose control on the complications of diabetes mellitus. 

 

Dr. David Brillon has been treating patients with both type 1 and type 2 diabetes for nearly 20 years. He has been involved in many diabetes studies (see Research Profile for current trials). He serves as the Program Director for the Fellowship Program in Endocrinology and Metabolism.

Insurances

Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.

  • AETNA [HMO]
  • AETNA [PPO]
  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • CIGNA
  • Empire Blue Cross/Blue Shield [NYPH Employees Only]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [EPO]
  • GHI
  • Health Republic
  • Medicaid
  • Medicare
  • Oscar
  • POMCO
  • Rockefeller University - CoreSource

Publications

EDIC Research Group. Epidemiology of Diabetes Interventions and Complications (EDIC): Design and implementation of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999; 22:99-111.
 

EDIC Research Group. Prolonged effect of intensive therapy on the risk of advanced complications in the Epidemiology of Diabetes Interventions and Complications (EDIC). NEJM 2000; 342:381-389.
 

Matthews DE, Harkin R, Battezati A and Brillon DJ. Splanchnic bed utilization of enteral alpha-keto-isocaproate in humans. Metabolism 1999; 48:1555-1563.
 

Poretsky L, Lesser M, Brillon D. Lack of postprandial leptin peaks in patients with type 2 diabetes mellitus. Diab Obes Metab 2000; 2:1-7.
 

DCCT/EDIC Research Group. Intensive diabetes therapy and carotid artery thickness in type 1 diabetes mellitus. NEJM 2003; 348:2294-2303.

Brillon DJ,Sison CP, Salbe AD, Poretsky L. Reproducibilty of a Glycemic Response to Mixed Meals in Type 2 Diabetes Mellitus. Horm Metab Res 2006; 38:536-542

Poretsky L, Brillon DJ, Ferrando S, Chui J, McELhiney , Ferenzi A, Sison CP, Haller I, Rabkin J. Endocrine effects of oral dhydroepiandosterone in men with HIV infection: a prospective , randomized, double-blind, placebo-controlled trial. Metabolism 2006; 55:858-870

Kern LM, Callahan MA, Brillon DJ, Vargas M, Mushlin, Al.  Glucose testing and insufficient follow-up of abnormal results: a cohort study.  BMC Health Serv res 6:87-92, 2006

Lubitz CC, Seley JJ, Rivera C, Sinha N, Brillon DJ.  the perils of inpatient hyperglycemia management: How we turned apathy into action.  Diabetes Spectrum 20:18-21, 2007

Bonds DE, Kurashige EM, Burgenstal R, Brillon D, Domanski M, Felicetta JV, Fonseca VA, Hall K, Hramiak I, Miller ME, Osei K, Simons-Morton DG. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial.  Am J Cardiol 2007; 99(S):80i-89i

ACCORD Study Group.  Effects of intensive glucose lowering in type 2 diabetes. N Eng J Med 358: 2545-2559